Streptococcus pneumoniae has a complex relationship with its obligate human host. On the
one hand, the pneumococci are highly adapted commensals, and their main reservoir on the …

Controlled human infection (CHI) trials, in which healthy volunteers are experimentally
infected, can accelerate the development of novel drugs and vaccines for infectious …

Background Infants in the UK were first offered a pneumococcal conjugate vaccine (PCV7)
in 2006, given at 2 and 4 months of age and a booster dose at 13 months (2+ 1 schedule). A …

Colonization of the human nasopharynx by pneumococcus is extremely common and is both
the primary reservoir for transmission and a prerequisite for disease. Current vaccines …

Streptococcus pneumoniae is the main bacterial pathogen involved in pneumonia.
Pneumococcal acquisition and colonization density is probably affected by viral co …

The ability of pneumococcal conjugate vaccine (PCV) to decrease transmission by blocking
the acquisition of colonization has been attributed to herd immunity. We describe the role of …

Background Bordetella pertussis is among the leading causes of vaccine-preventable
deaths and morbidity globally. Human asymptomatic carriage as a reservoir for community …

Streptococcus pneumoniae (Spn) is a common cause of respiratory infection, but also
frequently colonizes the nasopharynx in the absence of disease. We used mass cytometry to …

Abstract Vaccines targeting Streptococcus pneumoniae (Spn) are limited by dependence on
capsular polysaccharide and its serotype diversity. More broadly-based approaches using …

Summary Background In Kilifi (Kenya), a pneumococcal conjugate vaccine (PCV10) was
introduced in 2011 in infants (aged< 1 year, 3+ 0 schedule) with a catch-up campaign in …